Inspire licenses anti-infective for $13M upfront

Inspire Pharmaceuticals has licensed the U.S. and Canadian commercialization rights to InSite Vision's anti-infective AzaSite. InSite gained $13 million in an upfront fee and will get a $19 million milestone payment on the FDA's approval of its NDA. AzaSite is designed to treat pink eye.

In a release, InSite CEO Kumar Chandrasekaran said that "this platform will allow us to pursue additional anti-infective products and indications worldwide, supported by our expanded patent portfolio for both the AzaSite and DuraSite technologies.

- here's the release on the licensing deal

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.